Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Sponsor: Eisai Inc.
Summary
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Official title: An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Key Details
Gender
All
Age Range
4 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-07-08
Healthy Volunteers
Not specified
Conditions
Interventions
Rufinamide
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
Locations (2)
Generała Tadeusza Kościuszki 52
Kielce, Poland
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
Poznan, Poland